Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2008 3
2009 1
2010 3
2011 2
2012 1
2013 5
2014 2
2016 4
2017 6
2018 4
2019 5
2020 10
2021 6
2022 3
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M, Ratan R, Alcindor T, Schöffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Gounder M, et al. Among authors: pressey jg. N Engl J Med. 2023 Mar 9;388(10):898-912. doi: 10.1056/NEJMoa2210140. N Engl J Med. 2023. PMID: 36884323 Clinical Trial.
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Gounder M, et al. Among authors: pressey jg. Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6. Lancet Oncol. 2020. PMID: 33035459 Clinical Trial.
Molecular pathogenesis of rhabdomyosarcoma.
Xia SJ, Pressey JG, Barr FG. Xia SJ, et al. Among authors: pressey jg. Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104. doi: 10.4161/cbt.51. Cancer Biol Ther. 2002. PMID: 12170781 Review.
Herpes simplex virus oncolytic therapy for pediatric malignancies.
Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Friedman GK, et al. Among authors: pressey jg. Mol Ther. 2009 Jul;17(7):1125-35. doi: 10.1038/mt.2009.73. Epub 2009 Apr 14. Mol Ther. 2009. PMID: 19367259 Free PMC article. Review.
FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D, Shukla S, Gryder BE, Pradhan A, Donovan J, Sudha P, Vallabh S, Pyros A, Xu Y, Barski A, Szabo S, Turpin B, Pressey JG, Millay DP, Khan J, Kalinichenko VV, Kalin TV. Milewski D, et al. Among authors: pressey jg. Oncogene. 2021 Mar;40(12):2182-2199. doi: 10.1038/s41388-021-01694-9. Epub 2021 Feb 24. Oncogene. 2021. PMID: 33627785 Free PMC article.
Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Wang Y, Pandey RN, Roychoudhury K, Milewski D, Kalin TV, Szabo S, Pressey JG, Hegde RS. Wang Y, et al. Among authors: pressey jg. Mol Cancer Ther. 2021 May;20(5):803-815. doi: 10.1158/1535-7163.MCT-20-0749. Epub 2021 Mar 1. Mol Cancer Ther. 2021. PMID: 33649104 Free PMC article.
58 results